NUVL News and Press, Nuvalent Inc. From 11/09/23

Nuvalent Inc. (NUVL) is expected to report $-0.59 for Q3 2023

Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day PR Newswire CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targete...

2023-10-27 14:33:47 ET More on Nuvalent Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip Nuvalent prices $300 million stock offering Nuvalent announces $300M offering of Class A common stock For further details see: Nuvalent says Matthew ...

2023-10-27 04:39:28 ET More on Nuvalent Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip Nuvalent prices $300 million stock offering Nuvalent announces $300M offering of Class A common stock For further details see: Nuvalent director sell...

2023-10-23 02:50:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms. Immunotherapie...

2023-10-17 18:27:51 ET Nuvalent (NASDAQ: NUVL) is making hay while the sun shines, but investors are feeling a bit of a sunburn. The clinical-stage biotech announced a relatively large secondary share issue Monday night, and the market reacted by trading down the stock sharply Tuesd...

2023-10-17 04:34:43 ET More on Nuvalent Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip Nuvalent announces $300M offering of Class A common stock Nuvalent's drug shows promise in lung cancer patients in preliminary phase 1 data Seeking Alpha...

2023-10-16 08:16:09 ET More on Nuvalent Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip Nuvalent's drug shows promise in lung cancer patients in preliminary phase 1 data Nuvalent surges on Phase 1 data for lung cancer therapy Seeking Alpha&#...

2023-10-13 07:34:13 ET More on Nuvalent Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip Nuvalent surges on Phase 1 data for lung cancer therapy Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuvalent Fin...

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC PR Newswire Encouraging preliminary signs of activity observed in heavily pre-treated patients with ALK-positive NSCLC, i...